High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5399-5408

  Dieudonné, François Xavier ^a   Marion, Allison ^a   Haÿ, Eric ^a   Marie, Pierre Jacques ^a   Modrowski, Dominique ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; SYNDECAN 2; T CELL FACTOR PROTEIN; WNT PROTEIN; WNT3A PROTEIN;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; OSTEOSARCOMA; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SYNDECAN-2; TRANSCRIPTION, GENETIC; WNT PROTEINS;

EID: 77954378903     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0090     Document Type: Article

References (38)

1. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-41. (Pubitemid 39014554)
2. Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994;12:2614-20. (Pubitemid 24379647)
3. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006;6:1075-85. (Pubitemid 44203385)
4. Hoang BH, Kubo T, Healey JH, et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Res 2004;64:2734-9. (Pubitemid 38500609)
5. Guo Y, Zi X, Koontz Z, Kim A, et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 2007;25:964-71. (Pubitemid 47046444)
6. Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635-43. (Pubitemid 46984775)
7. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by β-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 2005;280:41342-51. (Pubitemid 41832191)
8. Villena J, Mainez J, Noguer O, et al. Syndecan-2 expression increases serum-withdrawal-induced apoptosis, mediated by redistribution of Fas into lipid rafts, in stably transfected Swiss 3T3 cells. Apoptosis 2006;11:2065-75. (Pubitemid 44691588)
9. Essner JJ, Chen E, Ekker SC. Syndecan-2. Int J Biochem Cell Biol 2006;38:152-6.
10. Orosco A, Fromigue O, Hay E, Marie PJ, Modrowski D. Dual involvement of protein kinase Cä in apoptosis induced by syndecan-2 in osteoblasts. J Cell Biochem 2006;98:838-50. (Pubitemid 43993400)
11. Modrowski D, Orosco A, Thevenard J, Fromigue O, Marie PJ. Syndecan-2 overexpression induces osteosarcoma cell apoptosis: implication of syndecan-2 cytoplasmic domain and JNK signaling. Bone 2005;37:180-9. (Pubitemid 40962425)
12. Orosco A, Fromigue O, Bazille C, et al. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res 2007;67:3708-15. (Pubitemid 46762156)
13. De Pollack C, Renier D, Hott M, Marie PJ. Increased bone formation and osteoblastic cell phenotype in premature cranial suture ossification (craniosynostosis). J Bone Miner Res 1996;11:401-7. (Pubitemid 26076390)
14. Yousfi M, Lasmoles F, Lomri A, Delannoy P, Marie PJ. Increased bone formation and decreased osteocalcin expression induced by reduced Twist dosage in Saethre-Chotzen syndrome. J Clin Invest 2001;107:1153-61.
15. Fromigue O, Kheddoumi N, Lomri A, Marie PJ, Body JJ. Breast cancer cells release factors that induced apoptosis in human bone marrow stromal cells. J Bone Miner Res 2001;16:1600-10.
16. Shibamoto S, Higano K, Takada R, Ito F, Takeichi M, Takada S. Cytoskeletal reorganization by soluble Wnt-3a protein signalling. Genes Cells 1998;3:659-70.
17. Obama H, Ozawa M. Identification of the domain of α-catenin involved in its association with β-catenin and plakoglobin (γ-catenin). J Biol Chem 1997;272:11017-20.
18. Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006;21:934-45.
19. Fromigue O, Hay E, Modrowski D, et al. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ 2006;13:1845-56. (Pubitemid 44542398)
20. Enomoto M, Hayakawa S, Itsukushima S, et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 2009;28:3197-208.
21. Munoz R, Moreno M, Oliva C, Orbenes C, Larrain J. Syndecan-4 regulates non-canonical Wnt signalling and is essential for convergent and extension movements in Xenopus embryos. Nat Cell Biol 2006;8:492-500.
22. Alexander CM, Reichsman F, Hinkes MT, et al. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 2000;25:329-32. (Pubitemid 30437323)
23. Alexopoulou AN, Multhaupt HA, Couchman JR. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 2007;39:505-28.
24. Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009;119:837-51.
25. Haydon RC, Deyrup A, Ishikawa A, et al. Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002;102:338-42. (Pubitemid 35265873)
26. Entz-Werle N, Lavaux T, Metzger N, et al. Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia 2007;9:678-88.
27. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/β-catenin pathway in conventional highgrade osteosarcoma. J Pathol 2010;220:24-33.
28. Matushansky I, Hernando E, Socci ND, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007;117:3248-57. (Pubitemid 350096982)
29. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19-39.
30. Guo Y, Rubin EM, Xie J, Zi X, Hoang BH. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res 2008;466:2039-45.
31. Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Invest New Drugs, In press 2010.
32. Fellenberg J, Dechant MJ, Ewerbeck V, Mau H. Identification of drug-regulated genes in osteosarcoma cells. Int J Cancer 2003;105:636-43. (Pubitemid 36687731)
33. Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol 2007;20:1085-94. (Pubitemid 47429197)
34. Morioka K, Tanikawa C, Ochi K, et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci 2009;100:1227-33.
35. Khyrul WA, LaLonde DP, Brown MC, Levinson H, Turner CE. The integrin-linked kinase regulates cell morphology and motility in a rho-associated kinase-dependent manner. J Biol Chem 2004;279:54131-9. (Pubitemid 40053149)
36. Fromigue O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 2008;283:30549-56.
37. Fears CY, Gladson CL, Woods A. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem 2006;281:14533-6. (Pubitemid 43855155)
38. Munesue S, Yoshitomi Y, Kusano Y, et al. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 2007;282:28164-74. (Pubitemid 47529519)